Stocks in play: NeonMind Biosciences Inc.

Announced that it is establishing a medical services division for the delivery of evidence-backed innovative treatments for a variety of mental health needs. This will include psychedelic modalities and other newer treatments for mood disorders such as depression. NeonMind is assembling a team of experts to plan and launch a chain of NeonMind-branded clinics in Canada. Working with health care communities and tailoring the services to local market needs, these clinics will offer various treatments for mental health, including psychedelic therapeutics and drug-enhanced psychotherapy. "Our vision is to build an integrated services platform and comprehensive set of programs aimed at delivering specialized treatments combined with traditional modalities for a variety of mental health conditions and right-sized for local needs," said Robert Tessarolo, President and CEO of NeonMind. "A major impetus for this strategic decision is that psychedelic drugs used to enhance psychotherapy are set to be a game-changing treatment tool, and infrastructure development is needed to provide access points for these innovative treatments." NeonMind Biosciences Inc. shares C.NEON are trading unchanged at $0.18.

Read:

• How Wearable Technology is Helping People to Actually Relax

• With Mental Health on the Decline, Top Companies Have Stepped in to Help

• Here’s Why Plant-Based Skin Care Products are Flying Off Shelves

• Watch These Companies as Progress Made to Unleash the Potential of Psychedelics for Mental Diseases

• Why Helium Could Be The Next Commodity To Boom

• Esports Betting Market Continues to Garner Serious Investor Interest in Q2 2021

• The Vape Market Could Hand Investors a $28.05 Billion Opportunity